Program
DWP212525
A development code. Also written as “DWP212525 XXmg”.
Its studies are mostly in Autoimmune Diseases, led by Daewoong Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceutical | 11 open or running | phase 1since Dec 6, 2024 | Dec 6, 2024 | Dec 30, 2026phase 1 · NCT06736587 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 6, 2024First study: phase 1 study in Autoimmune DiseasesFirst studyNCT06736587 · 84 planned · South Korea
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Autoimmune DiseasesNCT06736587
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06736587Autoimmune Diseases · South Korea | 1 | Recruiting | Dec 30, 2026 | 84 |
How it is read
Names in the registry
- “DWP212525 XXmg”, 1 entry
Codes read as this program: DWP212525.
Conditions, from the studies’ own filings
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.